A little history
myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.
To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:
- Development of state-of-the-art antigen prediction algorithms
- Discovery of novel, dark antigen targets called camyotopes
- (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
- The publication of high-impact scientific papers
- ISO and regulatory approval for clinical use of technology
- Securing valuable intellectual property with multiple patents
- Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
The people behind myNEO
Team
Cedric Bogaert
Chief Executive Officer & Co-founder
Bert Coessens PhD
Chief Operating Officer
Bruno Fant PhD
Chief Scientific Officer
Lien Lybaert PhD
Chief Development Officer
Lore Van Oudenhove
Chief Technology Officer
Lena Pfitzer
Senior data scientist
Gitta Boons PhD
Senior data scientist
Manon Montyne
Principal data scientist
Jens De Ceukeleire
Principal data scientist
Emiel Evenepoel
Junior bioinformatician
Marie Van Hecke PhD
Junior bioinformatician
Sofie Pontzeele
Executive assistant
Gitta Boons PhD
Senior data scientist
Gitta studied Biochemistry and Biotechnology at the University of Antwerp and performed her Master thesis on epigenetic cancer biomarkers at the lab for 'Translational Research and Microfluidics' at Paris Descartes University. She then pursued an FWO-funded PhD in oncogenetics at the Center for Oncological Research and the Center of Medical Genetics in Antwerp, during which her interest in bioinformatics led her to obtain a BanaBa in Bioinformatics at Howest.
At myNEO, Gitta was instrumental in the development of myCONSTRUCT, our construct design platform. She built its framework from the ground up and advanced the state-of-the-art by introducing a novel proteasome prediction metric to further ensure correct processing of target epitopes.